Screener
Bio-Rad Laboratories BIO Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $23.7 million and $23.0 million as of March 31, 2026 and December 31, 2025, respectively.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's equity method investments?
- Bio-Rad Laboratories (BIO) reported equity method investments of $23.7M in Q1 2026.
- How has Bio-Rad Laboratories's equity method investments changed year-over-year?
- Bio-Rad Laboratories's equity method investments increased by 3.0% year-over-year, from $23M to $23.7M.
- What is the long-term trend for Bio-Rad Laboratories's equity method investments?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's equity method investments has grown at a -70.1% compound annual growth rate (CAGR), from $9.56B to $23M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about Bio-Rad Laboratories's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude